T1	Participants 439 524	Two hundred twenty-four patients with MBC and no prior therapy for metastatic disease
T2	Participants 559 580	TLC D-99 (75 mg/m(2))
T3	Participants 584 608	doxorubicin (75 mg/m(2))
T4	Participants 110 159	first-line therapy of metastatic breast carcinoma
T5	Participants 1330 1378	Median age was 54 years in both treatment groups
